Pharsight

Novo Nordisk Inc patents expiration

1. Levemir patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US6011007 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR family patents

Family Patents

2. Levemir Flexpen patents expiration

LEVEMIR FLEXPEN's oppositions filed in EPO
LEVEMIR FLEXPEN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US6011007 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR FLEXPEN family patents

Family Patents

3. Levemir Flextouch patents expiration

LEVEMIR FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 5 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR FLEXTOUCH family patents

Family Patents

4. Levemir Innolet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6011007 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US6869930 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR INNOLET family patents

Family Patents

5. Levemir Penfill patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6869930 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US6011007 NOVO NORDISK INC Acylated insulin
Feb, 2014

(10 years ago)

US5750497 NOVO NORDISK INC Acylated insulin
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-117) May 18, 2015
M(M-115) Apr 06, 2015

Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

LEVEMIR PENFILL family patents

Family Patents

6. Norditropin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5633352 NOVO NORDISK INC Biosynthetic human growth hormone
May, 2014

(9 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN family patents

Family Patents

7. Norditropin Flexpro patents expiration

NORDITROPIN FLEXPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US6716198 NOVO NORDISK INC Injection device
Jun, 2021

(2 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 5 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: Treatment of disorders responsive to growth hormone

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN FLEXPRO family patents

Family Patents

8. Norditropin Nordiflex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5849704 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US5849700 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2015

(8 years ago)

US8841252 NOVO NORDISK INC Pharmaceutical formulation
Dec, 2017

(6 years ago)

US6235004 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-572) Oct 31, 2011
Orphan Drug Exclusivity(ODE) May 31, 2014

Drugs and Companies using SOMATROPIN ingredient

Market Authorisation Date: 23 January, 2015

Treatment: The long term treatment of growth failure due to lack of adequate endogenous growth hormone secretion in children

Dosage: INJECTABLE;INJECTION

More Information on Dosage

NORDITROPIN NORDIFLEX family patents

Family Patents

9. Novolog patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG family patents

Family Patents

10. Novolog Flexpen patents expiration

NOVOLOG FLEXPEN's oppositions filed in EPO
NOVOLOG FLEXPEN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297

(Pediatric)

NOVO NORDISK INC Injection syringe
Jul, 2019

(4 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

USRE41956

(Pediatric)

NOVO NORDISK INC Dose setting limiter
Jul, 2021

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG FLEXPEN family patents

Family Patents

11. Novolog Flextouch patents expiration

NOVOLOG FLEXTOUCH's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

US9486588 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US6899699 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8672898 NOVO NORDISK INC Automatic injection device with reset feature
Jan, 2022

(2 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US8684969 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Oct, 2025

(1 year, 5 months from now)

US9616180 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9861757 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US10376652 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US9108002 NOVO NORDISK INC Automatic injection device with a top release mechanism
Jan, 2026

(1 year, 8 months from now)

US10357616 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Jan, 2026

(1 year, 8 months from now)

US9775953 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

US10220155 NOVO NORDISK INC Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(2 years from now)

US8920383 NOVO NORDISK INC Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(2 years from now)

USRE46363 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US7686786 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Aug, 2026

(2 years from now)

US9687611 NOVO NORDISK INC Injection device with torsion spring and rotatable display
Feb, 2027

(2 years from now)

US9457154 NOVO NORDISK INC Injection device with an end of dose feedback mechanism
Sep, 2027

(3 years from now)

US9132239 NOVO NORDISK INC Dial-down mechanism for wind-up pen
Feb, 2032

(7 years from now)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG FLEXTOUCH family patents

Family Patents

12. Novolog Innolet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

USRE41956

(Pediatric)

NOVO NORDISK INC Dose setting limiter
Jul, 2021

(2 years ago)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG INNOLET family patents

Family Patents

13. Novolog Mix 50/50 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5547930 NOVO NORDISK INC AspB28 insulin crystals
Sep, 2013

(10 years ago)

US5840680 NOVO NORDISK INC ASPB28 insulin crystals
Sep, 2013

(10 years ago)

US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834422 NOVO NORDISK INC AspB28 insulin compositions
Sep, 2013

(10 years ago)

US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 26 August, 2008

Treatment: Method of treating a patient suffering from diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG MIX 50/50 family patents

Family Patents

14. Novolog Mix 70/30 patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5547930 NOVO NORDISK INC AspB28 insulin crystals
Sep, 2013

(10 years ago)

US5840680 NOVO NORDISK INC ASPB28 insulin crystals
Sep, 2013

(10 years ago)

US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834422 NOVO NORDISK INC AspB28 insulin compositions
Sep, 2013

(10 years ago)

US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: Method of treating a patient suffering from diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG MIX 70/30 family patents

Family Patents

15. Novolog Mix 70/30 Flexpen patents expiration

NOVOLOG MIX 70/30 FLEXPEN's oppositions filed in EPO
NOVOLOG MIX 70/30 FLEXPEN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5547930 NOVO NORDISK INC AspB28 insulin crystals
Sep, 2013

(10 years ago)

US5840680 NOVO NORDISK INC ASPB28 insulin crystals
Sep, 2013

(10 years ago)

US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834422 NOVO NORDISK INC AspB28 insulin compositions
Sep, 2013

(10 years ago)

US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: Method of treating a patient suffering from diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG MIX 70/30 FLEXPEN family patents

Family Patents

16. Novolog Mix 70/30 Penfill patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5547930 NOVO NORDISK INC AspB28 insulin crystals
Sep, 2013

(10 years ago)

US5840680 NOVO NORDISK INC ASPB28 insulin crystals
Sep, 2013

(10 years ago)

US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5834422 NOVO NORDISK INC AspB28 insulin compositions
Sep, 2013

(10 years ago)

US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

Drugs and Companies using INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 01 November, 2001

Treatment: Method of treating a patient suffering from diabetes mellitus

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG MIX 70/30 PENFILL family patents

Family Patents

17. Novolog Penfill patents expiration

NOVOLOG PENFILL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5618913 NOVO NORDISK INC Insulin analogues
Jun, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5626566 NOVO NORDISK INC Large dose pen
May, 2014

(9 years ago)

US5626566

(Pediatric)

NOVO NORDISK INC Large dose pen
Nov, 2014

(9 years ago)

US5693027 NOVO NORDISK INC Adaptor top
Dec, 2014

(9 years ago)

US5618913

(Pediatric)

NOVO NORDISK INC Insulin analogues
Dec, 2014

(9 years ago)

US5693027

(Pediatric)

NOVO NORDISK INC Adaptor top
Jun, 2015

(8 years ago)

US5866538 NOVO NORDISK INC Insulin preparations containing NaCl
Jun, 2017

(6 years ago)

US5866538

(Pediatric)

NOVO NORDISK INC Insulin preparations containing NaCl
Dec, 2017

(6 years ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient

Market Authorisation Date: 31 October, 2013

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

NOVOLOG PENFILL family patents

Family Patents

18. Prandimet patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6677358 NOVO NORDISK INC NIDDM regimen
Jun, 2018

(5 years ago)

Drugs and Companies using METFORMIN HYDROCHLORIDE; REPAGLINIDE ingredient

Market Authorisation Date: 23 June, 2008

Treatment: Use of repaglinide in combination with metformin to lower blood glucose

Dosage: TABLET;ORAL

How can I launch a generic of PRANDIMET before it's drug patent expiration?
More Information on Dosage

PRANDIMET family patents

Family Patents

19. Vagifem patents expiration

VAGIFEM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5860946 NOVO NORDISK INC Instrument for inserting a suppository
Jul, 2017

(6 years ago)

US7018992 NOVO NORDISK INC Hormone composition
Sep, 2022

(1 year, 7 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-122) Nov 25, 2012

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 25 November, 2009

Treatment: Treatment of atrophic vaginitis due to menopause

Dosage: TABLET;VAGINAL

How can I launch a generic of VAGIFEM before it's drug patent expiration?
More Information on Dosage

VAGIFEM family patents

Family Patents

20. Victoza patents expiration

VICTOZA's oppositions filed in EPO
VICTOZA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6458924 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US7235627 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2017

(6 years ago)

US6268343 NOVO NORDISK INC Derivatives of GLP-1 analogs
Aug, 2022

(1 year, 7 months ago)

US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(1 year, 3 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6004297 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE43834 NOVO NORDISK INC Injection syringe
Jan, 2019

(5 years ago)

USRE41956 NOVO NORDISK INC Dose setting limiter
Jan, 2021

(3 years ago)

USRE41956

(Pediatric)

NOVO NORDISK INC Dose setting limiter
Jul, 2021

(2 years ago)

US8846618 NOVO NORDISK INC Stable formulation of modified GLP-1
Jun, 2022

(1 year, 9 months ago)

US8846618

(Pediatric)

NOVO NORDISK INC Stable formulation of modified GLP-1
Dec, 2022

(1 year, 3 months ago)

US6268343

(Pediatric)

NOVO NORDISK INC Derivatives of GLP-1 analogs
Feb, 2023

(1 year, 1 month ago)

US8579869 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(9 months ago)

US8579869

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Dec, 2023

(3 months ago)

US7762994 NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
May, 2024

(a month from now)

US7762994

(Pediatric)

NOVO NORDISK INC Needle mounting system and a method for mounting a needle assembly
Nov, 2024

(7 months from now)

US8114833

(Pediatric)

NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Feb, 2026

(1 year, 9 months from now)

US9265893 NOVO NORDISK INC Injection button
Sep, 2032

(8 years from now)

US9265893

(Pediatric)

NOVO NORDISK INC Injection button
Mar, 2033

(8 years from now)

US9968659 NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jan, 2037

(12 years from now)

US9968659

(Pediatric)

NOVO NORDISK INC Liraglutide in cardiovascular conditions
Jul, 2037

(13 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-176) Apr 22, 2019
New Patient Population(NPP) Jun 17, 2022
New Indication(I-750) Aug 25, 2020
Pediatric Exclusivity(PED) Dec 17, 2022
M(M-115) Apr 06, 2015
New Chemical Entity Exclusivity(NCE) Jan 25, 2015

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

VICTOZA family patents

Family Patents